ANKE BIO(SZ:300009) Zhi Tong Cai Jing·2025-10-21 00:05Core Viewpoint - Anke Bio (300009.SZ) announced the presentation of its self-developed biological innovative drug, recombinant anti-HER2 humanized HuA21 monoclonal antibody injection, at the European Society for Medical Oncology (ESMO) annual meeting in Berlin from October 17 to 21, 2025, showcasing promising clinical research results for treating HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma [1] Group 1 - The clinical research data presented at ESMO further confirms the good anti-tumor activity and tolerable safety of HuA21 in combination with trastuzumab and chemotherapy for HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma [1] - The positive clinical data supports the progression to Phase III clinical trials, accelerating the drug development process [1] - The encouraging results will provide strong support for the market prospects of the product, enhancing the future market competitiveness of the company's offerings [1]